

Transplant and Cell Therapies Committee

THURSDAY, APRIL 30 • 3:00 – 4:30 PM PT • GARDEN ROOM (ATRIUM LOBBY LEVEL)

Agenda

1. Pending Studies

- a. EA 4241: A Two Cohort Randomized Study for Patients with High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse. *Sairah Ahmed, MD*

2. New Concept for discussion

- a. HA-1 TCR-T Cell Therapy for Post-HCT Hematologic Malignancy Relapse.
Marie Bleakley, Elizabeth Krakow, MD
- b. A Phase II Randomized Study Comparing Total Marrow and Lymphoid Irradiation (TMLI with Fractionated Total Body Irradiation (FTBI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) in Patients with Acute Lymphoblastic Leukemia. *Monzr M. Al Malki, MD*

3. Active Protocol Updates

- a. Plasma Cell Disorders
 - SWOG 2213: Phase 3 randomized trial of daratumumab, cyclophosphamide, bortezomib and dexamethasone (D-VCD) induction followed by autologous stem cell transplant or D-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis. *Patrick Hagen, MD*
- b. NHL
 - i. SWOG 2114: A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma. *Brian Hess, MD*
 - ii. EA 4232: PTCL-STAT (Stem-cell Transplant AuTologous). *Marc Hoffmann, MD*

4. MyeloMatch Update

- a. MM3TCT-A03: A Two Cohort, Randomized, Open-Label, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined with Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study. *Stephanie Tsai, MD, MS*